Dr. Bloor (CEO Videregen Limited) has over 30 years of experience in medical devices and regenerative medicine, with key expertise and leadership in strategic R&D, clinical compliance, and regulation specific to these areas having worked in US multinationals (J&J, Covidien/Medtronic) and UK start-up companies.

Formerly Chief Scientific Officer at Tissue Science Laboratories (TSL) plc., where Dr Bloor led the development of TSL’s unique regenerative tissue-based technology which was successfully commercialized in the EU, USA and Australasia. TSL listed on the Alternative Investment Market (AIM) via IPO, and was subsequently acquired by Covidien/Medtronic where Dr. Bloor became Vice President of R&D.

After the integration of TSL technology into Covidien/Medtronic, Dr. Bloor founded Videregen with a spin-out of world-leading tissue engineering IP from UK research organizations. Via angel investment and regional VC’s leveraged by UK and European Horizon 2020 grants, Dr. Bloor has led Videregen through preclinical and manufacturing development, and regulatory approval with the first human clinical trial imminent.

Dr. Pryhuber has been a neonatologist for over 30 years, caring for newborn infants who need the support of a Neonatal Intensive Care Unit for the first days to months of their lives. For over 20 years, she has also been an active researcher and author in fields of human lung injury and neonatal immunology in the Departments of Pediatrics and Environmental Medicine at the University of Rochester Medical Center. The majority of her work is focused on respiratory problems occurring in children due to prematurity, environmental exposures and infections. Dr. Pryhuber collaborates extensively with other investigators and doctors in many medical centers and fields of study, including neonatology, pulmonology, infectious disease, obstetrics/perinatology, immunology, microbiology, pathology, molecular biology and genomics, perinatal development and disease, with an ultimate goal is to reduce respiratory morbidity in children, especially those born prematurely. Dr. Pryhuber has led for the last 5 years, the Human Tissue Core for the Lung Development Molecular Atlas Program (LungMAP HTC). In partnership with the UNOS transplant network, the LungMAP HTC has created an extensive repository of consented, transplant-quality pediatric research tissues that provides multiple research centers with unique opportunities to explore the developing human respiratory tract and immune system in an unusually high quality and holistic manner (see LungMAP.net; LGEA Web Portal). Our success with building a pediatric lung tissue repository that includes many additional components of the immune system is unique and so valuable to translating from basic science laboratories to the bedside of infants and children.

Laura LeGuin, BSN serves as the Research and Donation Support Coordinator for LOPA – the Louisiana Organ Procurement Agency. She started her career at LOPA in 2011 as a Tissue Recovery Coordinator, moved to the role as a Quality Support Coordinator where she also began the Neonatal Donation Program in 2013. In 2017 the role of Research and Donation Support Coordinator was created where Laura’s main focus is the Neonatal Donation Program while also assisting with the Research Department.